TY - JOUR
T1 - Long-Term Outcomes After Cardiac Arrest
T2 - Protocol for the Extended Follow-Up Sub-Study of the STEPCARE Trial
AU - Lilja, Gisela
AU - Töniste, Dorit
AU - Bass, Frances
AU - Jakobsen, Janus Christian
AU - Nielsen, Niklas
AU - Skrifvars, Markus B.
AU - Ullén, Susann
AU - Dankiewicz, Josef
AU - Levin, Helena
AU - Hästbacka, Johanna
AU - Knappe, Marion Moseby
AU - Saxena, Manoj
AU - Wise, Matt P.
AU - Young, Paul
AU - Aneman, Anders
AU - Ameloot, Koen
AU - Cole, Jade M.
AU - Cronberg, Tobias
AU - Delaney, Anthony
AU - Druwé, Patrick
AU - During, Joachim
AU - Graf, Tobias
AU - Haenggi, Matthias
AU - Heimburg, Katarina
AU - Itens, Manuela
AU - Barkholt, Caroline Kamp
AU - Keeble, Thomas R.
AU - Leithner, Christoph
AU - Lybeck, Anna
AU - Lundin, Andreas
AU - McGuigan, Peter
AU - Mengel, Annerose
AU - Oksanen, Tuomas
AU - Ridgway, John
AU - Romundstad, Luis
AU - Schrag, Claudia
AU - Stammet, Pascal
AU - Tippett, Anna
AU - Thomas, Matthew
AU - Tirkkonen, Joonas
AU - Undén, Johan
AU - Venkatesh, Bala
AU - Tiainen, Marjaana
AU - Hammond, Naomi
N1 - Publisher Copyright:
© 2025 The Author(s). Acta Anaesthesiologica Scandinavica published by John Wiley & Sons Ltd on behalf of Acta Anaesthesiologica Scandinavica Foundation.
PY - 2025
Y1 - 2025
N2 - Background: The international multi-center randomized controlled STEPCARE-trial will investigate optimal management of sedation, temperature, and mean arterial pressure (MAP) during intensive care in out-of-hospital cardiac arrest (OHCA) patients due to various etiologies. The primary outcome is mortality at 6 months. This protocol describes an extended follow-up sub-study of the STEPCARE-trial with the main objective to provide detailed long-term outcomes for survivors and caregivers. It will focus on potential neuroprotection and improved recovery for different targets of sedation, temperature, and MAP management at 6 and 12 months post-OHCA. Methods: All survivors and one caregiver per survivor at selected STEPCARE sites will be invited to participate. Randomization is stratified by site. This sub-study extends the main STEPCARE follow-up at 6 months by undertaking detailed assessments, face-to-face meetings, inclusion of a caregiver, and repeating the assessments at 12 months. Our main outcome for survivors is cognitive function measured by the Montreal Cognitive Assessment, and for caregivers, the caregiver burden measured by the Zarit Burden Interview. Additional outcomes include symptoms of anxiety, depression, post-traumatic stress disorder, fatigue, physical function, life satisfaction, and life impact (disability), assessed by psychometrically robust measures. The estimated sample size is 600. Efforts to improve interrater reliability and decrease missing data are integral to the study design. Conclusion: These detailed long-term outcomes will explore the possible benefits or risks of fever, sedation, and blood pressure management in post-OHCA survivors. Additionally, this study will explore survivorship after cardiac arrest from various perspectives, including different causes of arrest. ClinicalTrials.gov: NCT0207942.
AB - Background: The international multi-center randomized controlled STEPCARE-trial will investigate optimal management of sedation, temperature, and mean arterial pressure (MAP) during intensive care in out-of-hospital cardiac arrest (OHCA) patients due to various etiologies. The primary outcome is mortality at 6 months. This protocol describes an extended follow-up sub-study of the STEPCARE-trial with the main objective to provide detailed long-term outcomes for survivors and caregivers. It will focus on potential neuroprotection and improved recovery for different targets of sedation, temperature, and MAP management at 6 and 12 months post-OHCA. Methods: All survivors and one caregiver per survivor at selected STEPCARE sites will be invited to participate. Randomization is stratified by site. This sub-study extends the main STEPCARE follow-up at 6 months by undertaking detailed assessments, face-to-face meetings, inclusion of a caregiver, and repeating the assessments at 12 months. Our main outcome for survivors is cognitive function measured by the Montreal Cognitive Assessment, and for caregivers, the caregiver burden measured by the Zarit Burden Interview. Additional outcomes include symptoms of anxiety, depression, post-traumatic stress disorder, fatigue, physical function, life satisfaction, and life impact (disability), assessed by psychometrically robust measures. The estimated sample size is 600. Efforts to improve interrater reliability and decrease missing data are integral to the study design. Conclusion: These detailed long-term outcomes will explore the possible benefits or risks of fever, sedation, and blood pressure management in post-OHCA survivors. Additionally, this study will explore survivorship after cardiac arrest from various perspectives, including different causes of arrest. ClinicalTrials.gov: NCT0207942.
KW - caregivers
KW - cognition
KW - follow-up studies
KW - out-of-hospital cardiac arrest
KW - outcomes
KW - randomized controlled trial
U2 - 10.1111/aas.70114
DO - 10.1111/aas.70114
M3 - Article
C2 - 40856035
AN - SCOPUS:105014627785
SN - 0001-5172
VL - 69
JO - Acta Anaesthesiologica Scandinavica
JF - Acta Anaesthesiologica Scandinavica
IS - 9
M1 - e70114
ER -